記住我
On 6 February 2023, Janssen announced via press release positive results for its investigational drug nipocalimab for the treatment of pregnant adults at high risk for severe hemolytic disease of the fetus and newborn (HDFN). The majority of the 14 participants enrolled in the open-label phase 2 UNITY trial achieved a live birth after gestational week 32 without requiring intrauterine transfusion, meeting the trial’s primary endpoint.
The Clinical Pipeline is a column on translational and clinical research, from bench to bedside.
留言 (0)